| Barchart Demo Center |
$2.06
+0.01 (+0.49%)
as of May 31, 2024
as of May 31, 2024
| Profile | |
|---|---|
| Ticker Symbol | TFFP |
| Exchange | NASDAQ |
| Contact Information |
1751 River Run Suite 400 Fort Worth, TX USA P: 817-438-6168 |
| CEO/President | Harlan Weisman |
| Earnings at a Glance | ||||
|---|---|---|---|---|
| Earnings | 03/31/24 -2.40 |
12/31/23 -1.23 |
09/30/23 -2.25 |
06/30/23 -3.50 |
| Price Earnings Ratio | N/A | |||
| EPS Growth | 45.06 | |||
| Most Recent Earnings ($) | -2.40 | |||
| Annual EPS ($) | -10.16 | |||
| Business Summary | |
|---|---|
| TFF Pharmaceuticals Inc. is an early-stage biopharmaceutical company. It is focused on the development and commercialization of inhalation products for the treatment of chronic respiratory diseases and lung conditions. TFF Pharmaceuticals Inc. is based in Austin Texas. | |
| Industry/Sector | SIC-2834 Pharmaceutical Preparations Medical - Biomedical |